Ardent Health Partners (NYSE:ARDT) Updates FY 2025 Earnings Guidance

Ardent Health Partners (NYSE:ARDT) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.730-2.010 for the period, compared to the consensus EPS estimate of 1.930. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.3 billion.

Ardent Health Partners Stock Up 8.6 %

Shares of ARDT stock traded up $1.21 during trading on Thursday, reaching $15.22. 343,997 shares of the company’s stock were exchanged, compared to its average volume of 369,008. The company has a quick ratio of 1.78, a current ratio of 1.91 and a debt-to-equity ratio of 0.78. Ardent Health Partners has a twelve month low of $13.63 and a twelve month high of $20.72. The firm’s fifty day moving average price is $15.29 and its 200-day moving average price is $16.87.

Ardent Health Partners (NYSE:ARDT) last posted its earnings results on Wednesday, February 26th. The company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.31. The business had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.48 billion. As a group, research analysts predict that Ardent Health Partners will post 1.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on ARDT shares. Stephens reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Ardent Health Partners in a report on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Ardent Health Partners in a report on Thursday, November 14th. Leerink Partners upped their price objective on Ardent Health Partners from $23.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Truist Financial cut their target price on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $20.00 target price on shares of Ardent Health Partners in a research report on Tuesday, December 17th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Ardent Health Partners presently has an average rating of “Buy” and a consensus target price of $21.36.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.